Amgen, Inc. (NASDAQ:AMGN) declared a quarterly dividend on Tuesday, October 23rd, RTT News reports. Investors of record on Friday, November 16th will be paid a dividend of 1.32 per share by the medical research company on Friday, December 7th. This represents a $5.28 annualized dividend and a dividend yield of 2.73%. The ex-dividend date of this dividend is Thursday, November 15th.

Amgen has increased its dividend by an average of 23.5% annually over the last three years and has increased its dividend every year for the last 7 years. Amgen has a payout ratio of 37.8% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Amgen to earn $14.31 per share next year, which means the company should continue to be able to cover its $5.28 annual dividend with an expected future payout ratio of 36.9%.

Shares of Amgen stock opened at $193.16 on Friday. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84. Amgen has a 1 year low of $163.31 and a 1 year high of $210.19. The company has a market cap of $125.93 billion, a P/E ratio of 15.35, a P/E/G ratio of 2.05 and a beta of 1.37.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.24. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The firm had revenue of $5.90 billion during the quarter, compared to the consensus estimate of $5.78 billion. During the same period in the previous year, the firm posted $3.27 EPS. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, analysts forecast that Amgen will post 14.24 EPS for the current fiscal year.

AMGN has been the subject of several analyst reports. Cann reiterated a “buy” rating and issued a $224.00 price target on shares of Amgen in a report on Monday, July 30th. Oppenheimer reiterated a “buy” rating and issued a $224.00 price target on shares of Amgen in a report on Monday, July 30th. Mizuho reiterated a “buy” rating and issued a $200.00 price target on shares of Amgen in a report on Friday, July 27th. Goldman Sachs Group reiterated a “buy” rating and issued a $228.00 price target on shares of Amgen in a report on Friday, July 27th. Finally, Royal Bank of Canada set a $193.00 price target on Amgen and gave the company a “buy” rating in a report on Friday, July 27th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company’s stock. Amgen currently has a consensus rating of “Hold” and an average price target of $204.55.

COPYRIGHT VIOLATION NOTICE: “Amgen, Inc. (AMGN) to Issue Quarterly Dividend of $1.32” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dailypolitical.com/2018/11/10/amgen-inc-amgn-to-issue-quarterly-dividend-of-1-32.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: Compound Interest and Why It Matters When Investing

Dividend History for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.